Effects of royal jelly on liver paraoxonase activity in rats treated with cisplatin;Sisplatin ile tedavi edilen sıçanlarda karaciǧer paraoksonaz aktivitesi üzerine arı sütünün etkileri

Turkish Journal of Medical Sciences

Volumn 42, Issue 3, 2012, Pages 367-375

  Yildirim, Serap ^a   KaradenIz, Ali ^a   Karakoç, Akar ^a   Yildirim, Abdulkadir ^a   Kalkan, Yildiray ^a   ŞImşek, Nejdet ^a  

^a ATATÜRK UNIVERSITY   (Turkey)

Author keywords

Arylesterase; Cisplatin; Oxidative stress; Paraoxonase; Royal jelly

Indexed keywords

ALANINE AMINOTRANSFERASE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; BALEN ROYAL JELLY; CASPASE 3; CISPLATIN; ROYAL JELLY; SCAVENGER; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL TISSUE; ANTIAPOPTOTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CELL COUNT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; LIVER; LIVER HOMOGENATE; LIVER PROTECTION; LIVER TOXICITY; NONHUMAN; RAT; SINGLE DRUG DOSE;

EID: 84859772456     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-1102-1373     Document Type: Article

References (35)

1. Guo H, Saiga A, Sato M, Miyazawa I, Shibata M, Takahata Y et al. Royal jelly supplementation improves lipoprotein metabolism in humans. J Nutr Sci Vitaminol (Tokyo) 2007; 53: 345-8.
2. Guo H, Ekusa A, Iwai K, Yonekura M, Takahata Y, Morimatsu F. Royal jelly peptides inhibit lipid peroxidation in vitro and in vivo. J Nutr Sci Vitaminol (Tokyo) 2008; 54: 191-5.
3. Şimşek N, Karadeniz A, Bayraktaroǧlu AG. Effects of L-carnitine, royal jelly and pomegranate seed on peripheral blood cells in rats. Kafk as Univ Vet Fak Derg 2009; 15: 63-9.
4. Türk G, Ateşşahin A, Sönmez M, Ceribaşi AO, Yüce A. Improvement of cisplatin-induced injuries to sperm quality, the oxidant-antioxidant system, and the histologic structure of the rat testis by ellagic acid. Fertil Steril 2008; 89: 1474-81.
5. Gottfried M, Ramlau R, Krzakowski M, Ziolo G, Olechnowicz H, Koubkova L et al. Cisplatin-based three drugs combination (NIP) as induction and adjuvant treatment in locally advanced non-small cell lung cancer: final results. J Thorac Oncol 2008; 3: 152-7.
6. Liao Y, Lu X, Lu C, Li G, Jin Y, Tang H. Selection of agents for prevention of cisplatin-induced hepatotoxicity. Pharmacol Res 2008; 57: 125-31.
7. Jiang M, Dong Z. Regulation and pathological role of p53 in cisplatin nephrotoxicity. J Pharmacol Exp Ther 2008; 327: 300-7.
8. Cayir K, Karadeniz A, Yildirim A, Kalkan Y, Karakoc A, Keles M et al. Protective effect of L-carnitine against cisplatininduced liver and kidney oxidant injury in rats. Cent Eur J Med 2009; 4: 184-91.
9. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005; 46: 1239-47.
10. Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoproteindeficient serum: relevance to diabetes. Atherosclerosis 2006; 187: 74-81.
11. Selek Ş, Alp R, Ilhan Alp S, Taşkin A. Relationship between PON1 phenotype and headache duration in migraine patients. Turk J Med Sci 2011; 41: 177-184.
12. Yildirim A, Aslan Ş, Ocak T, Yildirim S, Kara F, Şahin YN. Serum paraoxonase/arylesterase activities and malondialdehyde levels in trauma patients. EAJM 2007; 39: 85-8.
13. Toker A, Kadi M, Yildirim AK, Aksoy H, Akçay F. Serum lipid profile paraoxonase and arylesterase activities in psoriasis. Cell Biochem Funct 2009; 27: 176-80.
14. Demircioǧlu RI, Usta B, Sert H, Muslu B, Gözdemir M. Taurine is protective against oxidative stress during cold ischemia in the rat kidney. Turk J Med Sci 2011; 41: 843-849.
15. Al-Majed AA. Carnitine deficiency provokes cisplatin-induced hepatotoxicity in rats. Basic Clin Pharmacol Toxicol 2007; 100: 145-50.
16. Zamami Y, Takatori S, Goda M, Koyama T, Iwatani Y, Jin X et al. Royal jelly ameliorates insulin resistance in fructosedrinking rats. Biol Pharm Bull 2008; 31: 2103-7.
17. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
18. Beltowski J, Jamroz-Wisniewska A, Borkowska E, Wojcicka G. Differential effect of antioxidant treatment on plasma and tissue paraoxonase activity in hyperleptinemic rats. Pharmacol Res 2005; 51: 523-32.
19. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-38.
20. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007; 7: 3-18.
21. Kart A, Cigremis Y, Karaman M, Ozen H. Caffeic acid phenethyl ester (CAPE) ameliorates cisplatin-induced hepatotoxicity in rabbit. Exp Toxicol Pathol 2010; 62: 45-52.
22. Şanli A, Aydin S, Sarisoy ZA, Paksoy M, Ayduran E, Erdivanli ÖÇ. The protective effect of dexamethasone and lactate against cisplatin-induced ototoxicity. Turk J Med Sci 2011; 41: 467-74.
23. Gonzalvo MC, Gil F, Hernandez AF, Rodrigo L, Villanueva E, Pla A. Human liver paraoxonase (PON1): subcellular distribution and characterization. J Biochem Mol Toxicol 1998; 12: 61-9.
24. Ferré N, Camps J, Prats E, Vilella E, Paul A, Figuera L et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002; 48: 261-8.
25. Camuzcuoǧlu H, Toy H, Vural M, Camuzcuoǧlu A, Taşkin A, Çelik H. Serum paraoxonase and arylesterase activities in iron deficiency anemia during pregnancy. Turk J Med Sci 2011; 41: 185-191.
26. Goswami B, Tayal D, Gupta N, Mallika V. Paraoxonase: a multifaceted biomolecule. Clin Chim Acta 2009; 410: 1-12.
27. Hazar A, Dilmeç F, Göz M, Koçarslan A, Aydin MS, Demirkol AH. The paraoxonase 1 (PON1) gene polymorphisms in coronary artery disease in the southeastern Turkish population. Turk J Med Sci 2011; 41: 895-902.
28. Trudel K, Sinnett D, James RW, Delvin E, Amre D, Seidman E, et al. Iron-ascorbic acid-induced oxidant stress and its quenching by paraoxonase 1 in HDL and the liver: comparison between humans and rats. J Cell Biochem 2005; 96: 404-11.
29. Santos NA, Bezerra CS, Martins NM, Curti C, Bianchi ML, Santos AC. Hydroxyl radical scavenger ameliorates cisplatininduced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother Pharmacol 2008; 61: 145-55.
30. Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009; 61: 223-42.
31. Sadzuka Y, Shoji T, Takino Y. Effect of cisplatin on the activities of enzymes which protect against lipid peroxidation. Biochem Pharmacol 1992; 43: 1872-5.
32. Zhang JG, Lindup WE. Role of mitochondria in cisplatininduced oxidative damage exhibited by rat renal cortical slices. Biochem Pharmacol 1993; 45: 2215-22.
33. Kishimoto S, Miyazawa K, Terakawa Y, Ashikari H, Ohtani A, Fukushima S et al. Cytotoxicity of cis-[(1R,2R)-1,2-cyclohexanediamine-N, N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line. Jpn J Cancer Res 2000; 91: 1326-32.
34. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatininduced cell death always produced by apoptosis? Mol Pharmacol 2001; 59: 657-63.
35. Yüce A, Ateşşahin A, Ceribaşi AO, Aksakal M. Ellagic acid prevents cisplatin-induced oxidative stress in liver and heart tissue of rats. Basic Clin Pharmacol Toxicol 2007; 101: 345-9.